Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;16(1):e2024030.
doi: 10.4084/MJHID.2024.030. eCollection 2024.

Internal Medicine Ward with Hematological Skills for the Treatment of Complications Suffered by Hematological Patients on Therapy: Experience of Villa Betania Hospital in Rome

A Andriani  1 , L Marchetti  1 , F Rossi  1 , M A Perretti  1 , S Raja  1 , U Recine  1
Affiliations

Internal Medicine Ward with Hematological Skills for the Treatment of Complications Suffered by Hematological Patients on Therapy: Experience of Villa Betania Hospital in Rome

A Andriani et al. Mediterr J Hematol Infect Dis. .
No abstract available

Keywords: Comorbidity; Emergency Room; Hematological patients; Medical Complications.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no conflict of Interest.

Figures

Figure 1
Figure 1
Main reasons for hospitalization.
See this image and copyright information in PMC

References

    1. Low J, Smith A, George S, Roderick P, Davis C. How many patients with haematological malignancy need the facilities offered by a district general hospital? J Public Health Med. 2002 Sep;24(3):196–9. doi: 10.1093/pubmed/24.3.196. - DOI - PubMed
    1. Snowden JA, O’Connell S, Hawkins J, Dalley C, Jack A, Mannari D, McNamara C, Scott M, Shenton G, Soilleux E, Macbeth F Guideline Committee. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) J Clin Pathol. 2017 Jun;70(6):461–468. doi: 10.1136/jclinpath-2016-204029. - DOI - PubMed
    1. Kim K, Phelps MA. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab. Clin Pharmacokinet. 2023 Jun;62(6):789–806. doi: 10.1007/s40262-023-01240-8. - DOI - PMC - PubMed
    1. Paul B, Hamadeh I, Atrash S, Bhutani M, Voorhees P, Usmani SZ. Daratumumab subcutaneous formulation for the treatment of multiple myeloma. Expert Opin Biol Ther. 2020 Nov;20(11):1253–1259. doi: 10.1080/14712598.2020.1806231. - DOI - PubMed
    1. De Angelis G, Fiorini A, Trapè G, Panichi V, Chavez MG, Emanueli Cippitelli E, Innocenti V, Perazzini R, Talucci R, Topini G, Di Veroli A, Mercanti C, Natalino F, Tarnani M, Morucci M, Mastini C, Silvestri A, Andriani A, Montanaro M, Ciambella S, Latagliata R. Subcutaneous Daratumumab at Home Is a Safe and Effective Procedure for Frail Patients with Multiple Myeloma: A Myelhome Project Report. Blood. 2023;142(Supplement 1):7242. doi: 10.1182/blood-2023-187362. - DOI